Dual antiplatelet therapy with cilostazol in stroke patients with extracranial arterial stenosis or without arterial stenosis: A subgroup analysis of the CSPS.com trial

Abstract

Background:

We previously reported that dual antiplatelet therapy (DAPT) with cilostazol was superior to aspirin or clopidogrel for the prevention of recurrent stroke and vascular events in a subgroup analysis of intracranial arterial stenosis in the Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com), a randomized controlled trial.

Aims:

We conducted another subgroup analysis to investigate the benefit of DAPT with cilostazol in patients with extracranial arterial stenosis (ECAS) and those without arterial stenosis.

Methods:

We compared the risk of recurrent ischemic stroke, vascular events, and major bleeding between DAPT with cilostazol plus aspirin or clopidogrel and aspirin or clopidogrel alone in patients with ischemic stroke between 8 and 180 days before starting trial treatment and ECAS or without arterial stenosis.

Results:

The median follow-up period was 1.4 years. The risk of recurrent ischemic stroke (hazard ratio (HR): 1.04, 95% confidence interval (CI): 0.42–2.57) and vascular events (HR: 0.97, 95% CI: 0.42–2.24) did not differ between the two groups for the 253 patients with ECAS, whereas they were lower (HR: 0.36, 95% CI: 0.18–0.74 and HR: 0.47, 95% CI: 0.26–0.85, respectively) in the DAPT group for the 944 patients without arterial stenosis. The risk of major bleeding did not differ between the groups in patients with ECAS (HR: 0.58, 95% CI: 0.05–6.39) or without arterial stenosis (HR: 0.79, 95% CI: 0.27–2.26).

Conclusion:

DAPT with cilostazol might be beneficial for prevention of recurrent stroke and vascular events in patients without arterial stenosis but not in those with ECAS.

Data access statement:

We will make the deidentified participant data from this research available to the scientific community with as few restrictions as feasible, while retaining exclusive use until the publication of major output.

Keywords

Dual antiplatelet therapy cilostazol arterial stenosis stroke prevention

Get full access to this article

View all access options for this article.

References

Uchiyama

Toyoda

Omae

, et al Dual antiplatelet therapy using cilostazol in patients with stroke and intracranial arterial stenosis. J Am Heart Assoc 2021; 10: e02275. Published Online October 8 2021. DOI: 10.1161/JAHA.121.022575.

Hennigs

Matuszcak

Trepel

Körbelin

Vascular endothelial cells: heterogeneity and targeting approaches. Cells 2021; 10: 2712.

Igawa

Tani

Chijiwa

, et al Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells. Thromb Res 1990; 57: 617–623.

Yamamoto

Takahashi

Watanabe

, et al Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation. Circ J 2008; 72: 1844–1851.

Uchiyama

Demaerschalk

Goto

, et al Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 2009; 18: 482–490.

Toyoda

Uchiyama

Yamaguchi

, et al Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol 2019; 18: 539–548.

Toyoda

Uchiyama

Hoshino

, et al Protocol for cilostazol stroke prevention study for antiplatelet combination (CSPS.com): a randomized, open-label, parallel-group trial. Int J Stroke 2015; 10: 253–258.

The GUSTO investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–682.

Lovett

Coull

Rothwell

PM.

Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62: 569–573.

10.

Messas

Goudot

Halliday

, et al Management of carotid stenosis for primary and secondary prevention of stroke: state-of-the-art 2020: a critical review. Eur Heart J Suppl 2020; 22: M35–M42.

11.

Markus

Droste

Kaps

, et al Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005; 111: 2233–2240.

12.

Wong

Chen

, et al Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9: 489–497.

13.

Wang

Johnston

Wang

Clopidogrel with aspirin in minor stroke or transient ischemic attack. N Engl J Med 2013; 369: 1376–1377.

14.

Johnston

Easton

Farrant

, et al Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018; 379: 215–225.

15.

Esprit Study Group; Halkes

PHA

Gijn

van Kappelle

Koudstaal

Algra

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665–1673.

16.

Sacco

Diener

H-C

Yusuf

, et al Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238–1251.

17.

Asada

Yamashita

Sato

, et al Pathophysiology of atherothrombosis: mechanisms of thrombus formation on disrupted atherosclerotic plaques. Pathol Int 2020; 70: 309–322.

18.

Fuster

Moreno

Fayad

, et al Atherothrombosis and high-risk plaque: Part I: evolving concept. J Am Coll Cardiol 2005; 46: 937–954.

19.

Jang

Jin

Seo

, et al A meta-analysis of randomized controlled trials appraising the efficacy and safety of cilostazol after coronary artery stent implantation. Cardiology 2012; 122: 133–143.

20.

Toyoda

Omae

Hoshino

, et al Association of timing for starting dual antiplatelet treatment with cilostazol and recurrent stroke: a CSPS.com trial post-hoc analysis. Neurology 2022; 98: e983–e992.

21.

Ota

Eto

Kano

, et al Cilostazol inhibits oxidative stress–induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28: 1634–1639.

22.

Eikelboom

Hirsh

Spencer

, et al Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 Suppl): e89S–e119S.

23.

Yaghi

Raz

Yang

, et al Lacunar stroke: mechanisms and therapeutic implications. J Neurol Neurosurg Psychiat 2021; 92: 823–830.

24.

Regenhardt

Das

, et al Advances in understanding the pathophysiology of lacunar stroke: a review. JAMA Neurol 2018; 75: 1273–1281.

25.

McHutchison

Gordon

Appleton

, et al Cilostazol for secondary prevention of stroke and cognitive decline. Systematic review and meta-analysis. Stroke 2020; 51: 2374–2385.

26.

Kim

Lee

Kwon

, et al Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral hemorrhage (PICCASO): a multicenter, randomised controlled trial. Lancet Neurol 2018; 17: 509–518.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB